Celltrion Pharm’s Bio and CMO Sales Surpass Chemical Segment, Reaching 54% in H1

Celltrion Pharm’s business structure is changing rapidly, moving away from a chemical‑driven portfolio that was once anchored by the liver drug “Godeks.” Last year the company recorded, for the first time, combined bio‑pharma and contract‑manufacturing (CMO) sales that exceeded 50% of total revenue. In the first half of this year that share approached 54%, further widening the gap with its chemical segment. According to an analysis report by IBK Investment Securities, the combined bio‑pharma and CMO revenue share for the first half of 2026 was 53.8%, while the chemical business accounted for 46.4%, creating a 7.4‑percentage‑point difference. The shift highlights the growing importance of Celltrion Pharm’s bio‑pharma and CMO operations compared with its traditional chemical drug line, which has historically featured products such as the liver medication Godeks.